[
  {
    "ts": null,
    "headline": "China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds",
    "summary": "Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a...",
    "url": "https://finnhub.io/api/news?id=d1da8e4ba7fa3c6527faabe4d40dac0c2964112ba0c0656ee4cfc098549b6676",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750520769,
      "headline": "China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds",
      "id": 135456512,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a...",
      "url": "https://finnhub.io/api/news?id=d1da8e4ba7fa3c6527faabe4d40dac0c2964112ba0c0656ee4cfc098549b6676"
    }
  },
  {
    "ts": null,
    "headline": "Lilly expects orforglipron obesity results in third quarter",
    "summary": "(Reuters) -Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes.  Lilly expects to submit the non-diabetes Phase 3 data to global regulatory agencies by the end of the year, said Ken Custer, head of cardiometabolic health at the company.  Lilly said it plans to file for regulatory approvals for orforglipron as a diabetes treatment in 2026.",
    "url": "https://finnhub.io/api/news?id=faf4840732c6b686cf85d40c72262237e7fb72a076b2513a5b4b422d2ba62c8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750511160,
      "headline": "Lilly expects orforglipron obesity results in third quarter",
      "id": 135456174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes.  Lilly expects to submit the non-diabetes Phase 3 data to global regulatory agencies by the end of the year, said Ken Custer, head of cardiometabolic health at the company.  Lilly said it plans to file for regulatory approvals for orforglipron as a diabetes treatment in 2026.",
      "url": "https://finnhub.io/api/news?id=faf4840732c6b686cf85d40c72262237e7fb72a076b2513a5b4b422d2ba62c8a"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. At 40 weeks, all three doses (3 mg, 12 mg,",
    "url": "https://finnhub.io/api/news?id=c396dd7143c73f061e508d87b4d55770c0fee2bd81bd7249353e847abf274d54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750510860,
      "headline": "Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine",
      "id": 135456175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. At 40 weeks, all three doses (3 mg, 12 mg,",
      "url": "https://finnhub.io/api/news?id=c396dd7143c73f061e508d87b4d55770c0fee2bd81bd7249353e847abf274d54"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade)",
    "summary": "Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high valuation, and speculative pipeline raise concerns.",
    "url": "https://finnhub.io/api/news?id=c2d197414502e2a2e34cce5b8505463d9e7dc8c9bfda7ec1d729e7da4a066333",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750505400,
      "headline": "Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade)",
      "id": 135455322,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316503044/image_1316503044.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high valuation, and speculative pipeline raise concerns.",
      "url": "https://finnhub.io/api/news?id=c2d197414502e2a2e34cce5b8505463d9e7dc8c9bfda7ec1d729e7da4a066333"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone",
    "summary": "Eli Lilly and Company announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate...",
    "url": "https://finnhub.io/api/news?id=753dfb0217bfb5727fc76b8777e01b21b841e23fb1b77be21f34767f32d3af8f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750496460,
      "headline": "Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone",
      "id": 135458104,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate...",
      "url": "https://finnhub.io/api/news?id=753dfb0217bfb5727fc76b8777e01b21b841e23fb1b77be21f34767f32d3af8f"
    }
  }
]